The 4th Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group was held in Munich on 25-26 October 2018. As in previous years, this summit served as a reference meeting for in-depth discussions on the topic of recently completed and presented CVOTs. This year, focus was placed on the CVOTs CARMELINA, DECLARE-TIMI 58 and Harmony Outcomes. Trial implications for diabetes management and the impact of the new ADA/EASD consensus statement treatment algorithm were highlighted for diabetologists, cardiologists, endocrinologists, nephrologists and general practitioners. Discussions evolved from CVOTs to additional therapy options for heart failure (ARNI), knowledge gained for adjunct therapy of type 1 diabetes and, on the occasion of the 10 year anniversary of the FDA's "Guidance for Industry: "should CVOTs be continued and/or modified?" The 5th Cardiovascular Outcome Trial Summit will be held in Munich on 24-25 October 2019 ( http://www.cvot.org ).

3rd Department of Internal Medicine 1st Faculty of Medicine Charles University U Nemocnice 1 128 08 Prague 2 Czech Republic

Clalit Health Services and Technion Faculty of Medicine 3 Zivoni Street Haifa Israel

Clinic for Endocrinology Diabetes and Metabolic Diseases Clinical Center of Serbia Faculty of Medicine University of Belgrade Dr Subotica 13 Belgrade 11000 Serbia

Department of Cardiovascular and Metabolic Diseases IRCCS MultiMedica Via Milanese 300 20099 Sesto San Giovanni MI Italy

Department of Endocrinology Diabetology Nutrition CINFO CRNH IdF Jean VERDIER Hospital Paris 13 University Avenue du 14 Juillet 93140 Bondy France

Diabetes and Metabolic Disorders Dubrava University Hospital Avenija Gojka Šuška 6 10000 Zagreb Croatia

Forschergruppe Diabetes e 5 Ingolstaedter Landstraße 1 Neuherberg 85764 Munich Germany

Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain

Internal Medicine Department Clinical County Emergency Hospital Constanta Tomis Blvd No 145 900591 Constanța Romania

Zobrazit více v PubMed

ADA 9. Cardiovascular disease and risk management: standards of medical care in diabetes—2018. Diabetes Care. 2018;41(1):S86–S104. PubMed

Sharma A, et al. Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the TECOS trial. Diabetes Care. 2017;40(12):1763–1770. doi: 10.2337/dc17-1091. PubMed DOI

Barnett KN, et al. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with type 2 diabetes in Tayside, Scotland. Diabet Med. 2010;27(10):1124–1129. doi: 10.1111/j.1464-5491.2010.03075.x. PubMed DOI

Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38(8):1615–1621. doi: 10.2337/dc15-0099. PubMed DOI

Turnbull FM, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288–2298. doi: 10.1007/s00125-009-1470-0. PubMed DOI

Meinert CL, et al. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970;19:789–830. PubMed

Gerstein HC, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–2559. doi: 10.1056/NEJMoa0802743. PubMed DOI PMC

Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294(20):2581–2586. doi: 10.1001/jama.294.20.joc50147. PubMed DOI

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457–2471. doi: 10.1056/NEJMoa072761. PubMed DOI

FDA Background Document. Endocrinologic and metabolic drugs advisory committee meeting. 24/25 October 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM623913.pdf. Accessed 16 Jan 2019.

Guidance for industry diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, FDA, Editor. 2008.

Cefalu WT, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a diabetes care editors’ expert forum. Diabetes Care. 2018;41(1):14–31. doi: 10.2337/dci17-0057. PubMed DOI PMC

Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi: 10.1056/NEJMoa1307684. PubMed DOI

Zannad F, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. doi: 10.1016/S0140-6736(14)62225-X. PubMed DOI

Green JB, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi: 10.1056/NEJMoa1501352. PubMed DOI

Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–2257. doi: 10.1056/NEJMoa1509225. PubMed DOI

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827. PubMed DOI PMC

Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi: 10.1056/NEJMoa1607141. PubMed DOI

Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–1239. doi: 10.1056/NEJMoa1612917. PubMed DOI PMC

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720. PubMed DOI

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925. PubMed DOI

Marso SP, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723–732. doi: 10.1056/NEJMoa1615692. PubMed DOI PMC

Gerstein HC, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–328. doi: 10.1056/NEJMoa1203858. PubMed DOI

Schnell O, et al. Current perspectives on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2016;15(1):139. doi: 10.1186/s12933-016-0456-8. PubMed DOI PMC

Schnell O, et al. Updates on cardiovascular outcome trials in diabetes. Cardiovasc Diabetol. 2017;16(1):128. doi: 10.1186/s12933-017-0610-y. PubMed DOI PMC

Rosenstock J, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2018. [Epub ahead of print]. PubMed PMC

Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–1529. doi: 10.1016/S0140-6736(18)32261-X. PubMed DOI

Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389. PubMed DOI

Schwartz GG, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174. PubMed DOI

Schnell O, et al. Report from the 3rd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2018;17(1):30. doi: 10.1186/s12933-018-0667-2. PubMed DOI PMC

Schnell O, et al. Report from the 2nd Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes and Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2017;16(1):35. doi: 10.1186/s12933-017-0508-8. PubMed DOI PMC

Schnell O, et al. Report from the 1st Cardiovascular Outcome Trial (CVOT) Summit of the Diabetes & Cardiovascular Disease (D&CVD) EASD Study Group. Cardiovasc Diabetol. 2016;15:33. doi: 10.1186/s12933-016-0357-x. PubMed DOI PMC

Rosenstock J, et al. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. Cardiovasc Diabetol. 2018;17:39. doi: 10.1186/s12933-018-0682-3. PubMed DOI PMC

Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713–1722. doi: 10.1056/NEJMoa1615664. PubMed DOI

Shah AD, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 19 million people. Lancet Diabetes Endocrinol. 2015;3(2):105–113. doi: 10.1016/S2213-8587(14)70219-0. PubMed DOI PMC

McMurray JJV, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi: 10.1056/NEJMoa1409077. PubMed DOI

Seferovic JP, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–340. doi: 10.1016/S2213-8587(17)30087-6. PubMed DOI PMC

Velazquez EJ, et al. Angiotensin–neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2018;380(6):539–548. doi: 10.1056/NEJMoa1812851. PubMed DOI

Davies MJ, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2018;41(12):2669–2701. doi: 10.2337/dci18-0033. PubMed DOI PMC

de Ferranti SD, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843–2863. doi: 10.2337/dc14-1720. PubMed DOI PMC

Fox LA, et al. Persistence of abnormalities in white matter in children with type 1 diabetes. Diabetologia. 2018;61(7):1538–1547. doi: 10.1007/s00125-018-4610-6. PubMed DOI PMC

Musen G, et al. Cognitive function deficits associated with long-duration type 1 diabetes and vascular complications. Diabetes Care. 2018;41(8):1749–1756. doi: 10.2337/dc17-1955. PubMed DOI PMC

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653. doi: 10.1056/NEJMoa052187. PubMed DOI PMC

Hanefeld M, Frier BM, Pistrosch F. Hypoglycemia and cardiovascular risk: is there a major link? Diabetes Care. 2016;39(Supplement 2):S205–S209. doi: 10.2337/dcS15-3014. PubMed DOI

Standl E, et al. Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype. Diabetes Care. 2018;41(3):596–603. doi: 10.2337/dc17-1778. PubMed DOI

Warnes H, et al. Metabolic control in type 1 diabetes: is adjunctive therapy the way forward? Diabetes Ther. 2018;9(5):1831–1851. doi: 10.1007/s13300-018-0496-z. PubMed DOI PMC

Mathieu C, et al. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care. 2016;39(10):1702–1710. doi: 10.2337/dc16-0691. PubMed DOI

Pieber TR, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1) Diabetes Obes Metab. 2015;17(10):928–935. doi: 10.1111/dom.12494. PubMed DOI PMC

Perkins BA, et al. Sodium–glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial. Diabetes Care. 2014;37(5):1480–1483. doi: 10.2337/dc13-2338. PubMed DOI

Tamez HE, et al. Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus. J Diabetes Metab Disord. 2015;14:78. doi: 10.1186/s40200-015-0210-x. PubMed DOI PMC

Dandona P, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018;41(12):2552–2559. doi: 10.2337/dc18-1087. PubMed DOI

Henry RR, et al. Efficacy and safety of canagliflozin, a sodium–glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258–2265. doi: 10.2337/dc15-1730. PubMed DOI

Sands AT, et al. Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes. Diabetes Care. 2015;38(7):1181–1188. doi: 10.2337/dc14-2806. PubMed DOI PMC

Garg SK, et al. Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med. 2017;377(24):2337–2348. doi: 10.1056/NEJMoa1708337. PubMed DOI

Phend C. FDA advisors: tweak, don’t dump CV outcomes trials. 2018. https://www.medpagetoday.com/cardiology/prevention/75938. Accessed 06 Dec 2018.

Standl E, et al. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes. Lancet Diabetes Endocrinol. 2017;5(5):391–402. doi: 10.1016/S2213-8587(17)30033-5. PubMed DOI

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes